As of June 30, 2026, Connect Biopharma Holdings Limited carries a market capitalization of 149.88M, placing it among publicly traded companies globally. Its enterprise value stands at 118.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 149.88M |
| Enterprise Value | 118.99M |
Connect Biopharma Holdings Limited's next confirmed earnings release is scheduled for November 18, 2026.
| Earnings Date | 11/18/2026 |
As of June 30, 2026, Connect Biopharma Holdings Limited has 62.97M shares outstanding.
| Shares Outstanding | 62.97M |
These figures are as of June 30, 2026. The price-to-sales ratio is 46.59, and the price-to-book ratio stands at 5.58.
| PS Ratio | 46.59 |
| PB Ratio | 5.58 |
| P/TBV Ratio | 5.59 |
| P/FCF Ratio | -2.27 |
| P/OCF Ratio | -2.27 |
These figures are as of June 30, 2026. The EV/Sales ratio of 40.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 118.99M versus a market cap of 149.88M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 40.29 |
As of June 30, 2026, Connect Biopharma Holdings Limited maintains a current ratio of 2.37, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.37 |
| Quick Ratio | 2.11 |
| Debt / Equity | 2.22 |
| Debt / EBITDA | -0.01 |
Over the twelve months ended June 30, 2026, Connect Biopharma Holdings Limited posted a negative return on equity (ROE) of -140.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -109.34, reflecting losses generated across the asset base. The company generates approximately 46,503.94 in revenue per employee across its workforce of 63.50, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -140.51 |
| Return on Assets (ROA) | -109.34 |
| Revenue Per Employee | 46,503.94 |
| Employee Count | 63.50 |
Over the twelve months ended June 30, 2026, Connect Biopharma Holdings Limited recorded 196,000.00 in income tax expense. The company reported a pretax loss of -68.79M and -68.99M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 196,000.00 |
As of the close on November 16, 2026, Connect Biopharma Holdings Limited's stock has declined approximately 69.67% over the past 52 weeks. The 50-day moving average sits at 1.02, while the 200-day moving average is 2.10.
| 52-Week Price Change | -69.67% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 2.10 |
Over the twelve months ended June 30, 2026, Connect Biopharma Holdings Limited generated 2.95M in revenue and converted that into -68.99M in net income, yielding earnings per share of -1.19. EBITDA reached -69.73M, while operating income came in at -70.41M.
| Revenue | 2.95M |
| Operating Income | -70.41M |
| Pretax Income | -68.79M |
| Net Income | -68.99M |
| EBITDA | -69.73M |
| EBIT | -70.41M |
| Earnings Per Share (EPS) | -1.19 |
As of June 30, 2026, Connect Biopharma Holdings Limited holds 31.49M in cash and equivalents against 596,000.00 in total debt, resulting in a net debt position of -27.01M. Total book value stands at 26.86M, with working capital of 22.32M providing operational flexibility.
| Cash & Cash Equivalents | 31.49M |
| Total Debt | 596,000.00 |
| Net Debt | -27.01M |
| Equity (Book Value) | 26.86M |
| Book Value Per Share | 0.43 |
| Working Capital | 22.32M |
Connect Biopharma Holdings Limited produced -60.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -50,000.00 in capital expenditures, free cash flow totaled -60.63M - equivalent to -1.05 per share.
| Operating Cash Flow | -60.58M |
| Capital Expenditures | -50,000.00 |
| Free Cash Flow | -60.63M |
| FCF Per Share | -1.05 |
These figures cover the twelve months ended June 30, 2026. The operating margin of -2,384.49 and net profit margin of -2,336.30 provide insight into operational efficiency.
| Operating Margin | -2,384.49 |
| Pretax Margin | -2,329.66 |
| Profit Margin | -2,336.30 |
| EBITDA Margin | -2,361.29 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.26, meaning Connect Biopharma Holdings Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -13.26 |
| FCF Yield | -44.07 |
As of June 30, 2026, Connect Biopharma Holdings Limited has an Altman Z-Score of -13.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.36 |